AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30924895 — intervention group
Group type: EXPERIMENTAL
Intervention: PACT (Protect and Connect) intervention
Number of subjects: 230
Study 30924895 — intervention group
Group type: COMPARATOR
Intervention: HIV CTR control
Number of subjects: 230
Study 28957643 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with a ratio below LLN
Number of subjects: 17072
Study 28957643 — intervention group
Group type: COMPARATOR
Intervention: 5 μg tiotropium Respimat
Number of subjects: 17072
Study 28957643 — intervention group
Group type: COMPARATOR
Intervention: 18 μg HandiHaler
Number of subjects: 17072
Study 25810425 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional exercise training with inspiratory muscle training (8 weeks)
Number of subjects: 54
Study 25300273 — intervention group
Group type: EXPERIMENTAL
Intervention: LPCaC14:0 at age 6 months
Number of subjects: 726
Study 25300273 — intervention group
Group type: EXPERIMENTAL
Intervention: LPCaC14:0
Number of subjects: 726
Study 22472154 — intervention group
Group type: EXPERIMENTAL
Intervention: morphine (0.05 mg/kg) IV during gallbladder extraction and (0.15 mg/kg) for 40 min postoperatively
Number of subjects: 40
Study 22472154 — intervention group
Group type: COMPARATOR
Intervention: ketorolac (0.2 mg/kg) IV during gallbladder extraction and (0.7 mg/kg) for 40 min postoperatively
Number of subjects: 40
Study 22472154 — intervention group
Group type: EXPERIMENTAL
Intervention: morphine
Number of subjects: 40
Study 20353029 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Huanglian Wendan Decoction (HWD) 200 mL, twice a day
Number of subjects: 64
Study 20353029 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Huanglian Wendan Decoction (HWD)
Number of subjects: 64
Study 20353029 — intervention group
Group type: COMPARATOR
Intervention: Aniracetam 0.2 g (0.1 g for patients over 70), three times a day
Number of subjects: 64
Study 20353029 — intervention group
Group type: COMPARATOR
Intervention: Modified Huanglian Wendan Decoction (HWD) and Aniracetam
Number of subjects: 64
Study 17307300 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) adherence
Number of subjects: 163
Study 17307300 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to MI
Number of subjects: 163
Study 16107896 — intervention group
Group type: EXPERIMENTAL
Intervention: AML-82 protocol
Number of subjects: 209
Study 16107896 — intervention group
Group type: EXPERIMENTAL
Intervention: AML-87 protocol (based on BFM-87) with prophylactic cranial irradiation in high-risk patients
Number of subjects: 209
Study 16107896 — intervention group
Group type: EXPERIMENTAL
Intervention: AML-92/94 protocol (modified BFM-93) without maintenance therapy and prophylactic cranial irradiation
Number of subjects: 209
Study 11810342 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy (8 group sessions)
Number of subjects: 34
Study 11810342 — intervention group
Group type: COMPARATOR
Intervention: Waiting group (control)
Number of subjects: 34
Study 9231815 — intervention group
Group type: EXPERIMENTAL
Intervention: ET-1 infusion (0.5 ng/kg per minute for 60 minutes, then 1.0 ng/kg per minute for 60 minutes, and finally 2.0 ng/kg per minute for 60 minutes)
Number of subjects: 9
Study 9231815 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (20 mg BID)
Number of subjects: 9
Study 9231815 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (60 mg OD)
Number of subjects: 9
Study 8186511 — intervention group
Group type: EXPERIMENTAL
Intervention: L-phenylalanine (L-Phe) plus UVA irradiation
Number of subjects: 181
Study 8186511 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased L-phenylalanine dose
Number of subjects: 181
Study 8186511 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal L-phenylalanine dose
Number of subjects: 181
Study 3578096 — intervention group
Group type: EXPERIMENTAL
Intervention: White bread made from gluten-free flour
Number of subjects: 0
Study 3578096 — intervention group
Group type: COMPARATOR
Intervention: White bread made from regular flour
Number of subjects: 0
Study 3578096 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of gluten to gluten-free bread mix
Number of subjects: 0
Study 31066792 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency thermoablation
Number of subjects: 49
Study 31066792 — intervention group
Group type: COMPARATOR
Intervention: Complete saphenous vein stripping
Number of subjects: 49
Study 28728282 — intervention group
Group type: EXPERIMENTAL
Intervention: Tear film lipid layer thickness (LLT) measurement
Number of subjects: 473
Study 28728282 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular Surface Disease Index (OSDI) questionnaire
Number of subjects: 473
Study 28728282 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical analysis of LLT by age groups
Number of subjects: 473
Study 28728282 — intervention group
Group type: COMPARATOR
Intervention: Comparison of LLT by gender
Number of subjects: 473
Study 28728282 — intervention group
Group type: COMPARATOR
Intervention: Correlation analysis with TBUT, SchirmerⅠtest, meibomian gland loss rate
Number of subjects: 473
Study 25423323 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral salpingo-oophorectomy (BSO) without subsequent hormone therapy (HT)
Number of subjects: 8879
Study 25423323 — intervention group
Group type: COMPARATOR
Intervention: Retaining ovaries
Number of subjects: 8879
Study 22722891 — intervention group
Group type: EXPERIMENTAL
Intervention: Almond diet (56 g/day, replacing 20% of total daily calorie intake)
Number of subjects: 20
Study 22722891 — intervention group
Group type: COMPARATOR
Intervention: Control diet (NCEP step II diet)
Number of subjects: 20
Study 21979855 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver-containing soft silicone foam dressing (Mepilex Ag)
Number of subjects: 101
Study 21979855 — intervention group
Group type: COMPARATOR
Intervention: Silver sulfadiazine cream
Number of subjects: 101
Study 19860915 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose N-acetylcysteine (NAC)
Number of subjects: 155
Study 19860915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study 17085655 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (2 years)
Number of subjects: 400
Study 17085655 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 400
Study 15301636 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping self-efficacy measured using a modified Situational Confidence Questionnaire (SCQ)
Number of subjects: 126
Study 15301636 — intervention group
Group type: EXPERIMENTAL
Intervention: Early abstinence
Number of subjects: 126
Study 15301636 — intervention group
Group type: EXPERIMENTAL
Intervention: Early confidence
Number of subjects: 126
Study 11154711 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal verbal abuse during childhood
Number of subjects: 793
Study 11154711 — intervention group
Group type: COMPARATOR
Intervention: No maternal verbal abuse
Number of subjects: 793
Study 9086464 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum neurotoxin serotype C
Number of subjects: 3
Study 9086464 — intervention group
Group type: COMPARATOR
Intervention: Botulinum neurotoxin serotype A
Number of subjects: 3
Study 7959144 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin vaginal cream (2%)
Number of subjects: 184
Study 7959144 — intervention group
Group type: COMPARATOR
Intervention: Oral metronidazole
Number of subjects: 184
Study 2888637 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine (DPH) 50 mg
Number of subjects: 17
Study 2888637 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam 15 mg
Number of subjects: 17
Study 2888637 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 28759496 — intervention group
Group type: EXPERIMENTAL
Intervention: BVM with NC at 0 lpm
Number of subjects: 0
Study 28759496 — intervention group
Group type: EXPERIMENTAL
Intervention: BVM with NC at 5 lpm
Number of subjects: 0
Study 28759496 — intervention group
Group type: EXPERIMENTAL
Intervention: BVM with NC at 10 lpm
Number of subjects: 0
Study 28759496 — intervention group
Group type: EXPERIMENTAL
Intervention: BVM with NC at 15 lpm
Number of subjects: 0
Study 28759496 — intervention group
Group type: COMPARATOR
Intervention: BVM-only
Number of subjects: 0
Study 27686943 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide chemotherapy (75 mg/m2 daily, for 21 of 28 days for 12 cycles)
Number of subjects: 477
Study 27686943 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (50·4 Gy in 28 fractions of 1·8 Gy for 5 days per week up to 6·5 weeks)
Number of subjects: 477
Study 27686943 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide chemotherapy
Number of subjects: 477
Study 27686943 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 477
Study 25210752 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized exercise test
Number of subjects: 39
Study 23325917 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate (HC) meals
Number of subjects: 52
Study 23325917 — intervention group
Group type: COMPARATOR
Intervention: High-protein (HP) meals
Number of subjects: 52
Study 22136578 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based intensive program
Number of subjects: 534
Study 22136578 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer-based walking program
Number of subjects: 534
Study 22136578 — intervention group
Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 534
Study 19929975 — intervention group
Group type: EXPERIMENTAL
Intervention: AZ-ER (single oral 2-g dose)
Number of subjects: 598
Study 19929975 — intervention group
Group type: COMPARATOR
Intervention: AZ-IR (3 days, 500 mg once daily)
Number of subjects: 598
Study 16387893 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g i.v. carnitine
Number of subjects: 50
Study 16387893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 15508346 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone irrigation
Number of subjects: 12
Study 15508346 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 12
Study 12243707 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ketoconazole 600 mg/day for adults and 10 mg/kg per day for children for 30 days
Number of subjects: 96
Study 12243707 — intervention group
Group type: COMPARATOR
Intervention: Intra-lesional meglumine antimoniate (Glucantime) with 6-8 biweekly injections
Number of subjects: 96
Study 7900613 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin use (even infrequent)
Number of subjects: 90
Study 7900613 — intervention group
Group type: COMPARATOR
Intervention: No aspirin use
Number of subjects: 90
Study 2670331 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glucose (50%), insulin (80 units/I), and potassium (100 meq/l) (GIK) infused at a rate of 1 ml/kg/hr for up to 48 hours
Number of subjects: 22
Study 2670331 — intervention group
Group type: COMPARATOR
Intervention: Glucose (5%) and NaCl (0.225%) infused at the same rate (control)
Number of subjects: 22
Study 2670331 — intervention group
Group type: EXPERIMENTAL
Intervention: GIK
Number of subjects: 22
Study 2670331 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 22
Study 796942 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen
Number of subjects: 0
Study 796942 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 0
Study 31189509 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide (1.5 mg weekly subcutaneous injection)
Number of subjects: 9901
Study 31189509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9901
Study 31189509 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Number of subjects: 9901
Study 28471553 — intervention group
Group type: EXPERIMENTAL
Intervention: Parietal infiltration with ropivacaine
Number of subjects: 0
Study 25681529 — intervention group
Group type: EXPERIMENTAL
Intervention: CDP-choline 500mg
Number of subjects: 24
Study 25681529 — intervention group
Group type: EXPERIMENTAL
Intervention: CDP-choline 1000mg
Number of subjects: 24
Study 25681529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 25096607 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week progressive resistance training (2 times/week)
Number of subjects: 160
Study 25096607 — intervention group
Group type: COMPARATOR
Intervention: Relaxation control (RC, 2 times/week)
Number of subjects: 160
Study 21946980 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile bearing total knee prosthesis
Number of subjects: 92
Study 21946980 — intervention group
Group type: COMPARATOR
Intervention: Fixed bearing total knee prosthesis
Number of subjects: 92
Study 21165880 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental room (semicircular table, equal access to computer screen)
Number of subjects: 65
Study 21165880 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental room
Number of subjects: 65
Study 21165880 — intervention group
Group type: COMPARATOR
Intervention: Standard room
Number of subjects: 65
Study 17950093 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile intravenous insulin infusion (3 one-hour courses per week)
Number of subjects: 18
Study 17950093 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous insulin (3-4 injections per day)
Number of subjects: 18
Study 17950093 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile intravenous insulin infusion
Number of subjects: 18
Study 17950093 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous insulin
Number of subjects: 18
Study 16342005 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium administration
Number of subjects: 12
Study 16342005 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 12
Study 16342005 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium serum levels > 0.5 meq/l
Number of subjects: 12
Study 11928799 — intervention group
Group type: EXPERIMENTAL
Intervention: irinotecan
Number of subjects: 0
Study 11928799 — intervention group
Group type: COMPARATOR
Intervention: 5‐fluorouracil (5‐FU)‐based chemotherapy
Number of subjects: 0
Study 9456255 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplement with arginine and omega-3 fatty acids
Number of subjects: 64
Study 9456255 — intervention group
Group type: COMPARATOR
Intervention: Oral nutritional supplement without arginine and omega-3 fatty acids (Control)
Number of subjects: 64
Study 8943592 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 degrees anticlockwise rotation
Number of subjects: 90
Study 8943592 — intervention group
Group type: EXPERIMENTAL
Intervention: 180 degrees anticlockwise rotation then back to 90 degrees anticlockwise (overcorrected rotation)
Number of subjects: 90
Study 8943592 — intervention group
Group type: COMPARATOR
Intervention: No rotation (neutral position)
Number of subjects: 90
Study 1760685 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutured anastomoses
Number of subjects: 294
Study 1760685 — intervention group
Group type: COMPARATOR
Intervention: Stapled anastomoses
Number of subjects: 294
Study 6282524 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium canrenoate
Number of subjects: 6
Study 6282524 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 6
Study 6282524 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium canrenoate with furosemide and digoxin
Number of subjects: 6
Study 6282524 — intervention group
Group type: COMPARATOR
Intervention: Digoxin
Number of subjects: 6
Study 6282524 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 30713413 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable (this study focuses on exclusion criteria rather than a specific intervention)
Number of subjects: 1206
Study 30713413 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 1206
Study 28391912 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day for 4 weeks then 20 mg/day for 16 weeks
Number of subjects: 98
Study 28391912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 25512403 — intervention group
Group type: EXPERIMENTAL
Intervention: Faldaprevir with TID deleobuvir for 16 weeks
Number of subjects: 362
Study 25512403 — intervention group
Group type: EXPERIMENTAL
Intervention: Faldaprevir with TID deleobuvir for 28 weeks
Number of subjects: 362
Study 25512403 — intervention group
Group type: EXPERIMENTAL
Intervention: Faldaprevir with TID deleobuvir for 40 weeks
Number of subjects: 362
Study 25512403 — intervention group
Group type: EXPERIMENTAL
Intervention: Faldaprevir with BID deleobuvir for 28 weeks
Number of subjects: 362
Study 25512403 — intervention group
Group type: EXPERIMENTAL
Intervention: Faldaprevir with TID deleobuvir and no ribavirin for 28 weeks
Number of subjects: 362
Study 25250279 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous technique
Number of subjects: 35
Study 25250279 — intervention group
Group type: COMPARATOR
Intervention: Open surgical technique
Number of subjects: 35
Study 21719555 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin (60 μg/injection)
Number of subjects: 20
Study 21719555 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline injections)
Number of subjects: 20
Study 19302119 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% Caloric Restriction (CR)
Number of subjects: 48
Study 19302119 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5% Caloric Restriction plus Exercise (CR + EX)
Number of subjects: 48
Study 19302119 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Calorie Diet (LCD; 3724 kJ day(‐1) (890 kcal day(‐1)))
Number of subjects: 48
Study 19302119 — intervention group
Group type: COMPARATOR
Intervention: Healthy Diet (Control)
Number of subjects: 48
Study 17711731 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I: Propofol 2 microg/ml and Rimifentanil 2 ng/ml with fluid expansion of Hetastarch 5 ml/kg
Number of subjects: 90
Study 17711731 — intervention group
Group type: COMPARATOR
Intervention: Group II (Control): Propofol 4 microg/ml and Rimifentanil 4 ng/ml with fluid expansion of Hetastarch 10 ml/kg
Number of subjects: 90
Study 17711731 — intervention group
Group type: EXPERIMENTAL
Intervention: Group III: Propofol 4 microg/ml and Rimifentanil 4 ng/ml with fluid expansion of Hetastarch 10 ml/kg
Number of subjects: 90
Study 15007373 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (TN)
Number of subjects: 320
Study 15007373 — intervention group
Group type: COMPARATOR
Intervention: Nicotine nasal spray (NS)
Number of subjects: 320
Study 11727192 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting cephalosporine (ceftriaxone) with metronidazole
Number of subjects: 2481
Study 11727192 — intervention group
Group type: COMPARATOR
Intervention: Long-acting cephalosporine (ceftriaxone) without metronidazole
Number of subjects: 2481
Study 11727192 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-acting cephalosporines with metronidazole
Number of subjects: 2481
Study 11727192 — intervention group
Group type: COMPARATOR
Intervention: Short-acting cephalosporines without metronidazole
Number of subjects: 2481
Study 11727192 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad-spectrum penicillines with metronidazole
Number of subjects: 2481
Study 11727192 — intervention group
Group type: COMPARATOR
Intervention: Broad-spectrum penicillines without metronidazole
Number of subjects: 2481
Study 9517954 — intervention group
Group type: EXPERIMENTAL
Intervention: terbinafine
Number of subjects: 12
Study 9517954 — intervention group
Group type: COMPARATOR
Intervention: control (no terbinafine)
Number of subjects: 12
Study 7788917 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-up tilt testing at 60 degrees
Number of subjects: 150
Study 7788917 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-up tilt testing at 70 degrees
Number of subjects: 150
Study 7788917 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-up tilt testing at 80 degrees
Number of subjects: 150
Study 7788917 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose isoproterenol infusion during tilt testing at 60 degrees
Number of subjects: 150
Study 7788917 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose isoproterenol infusion during tilt testing at 70 degrees
Number of subjects: 150
Study 7788917 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose isoproterenol infusion during tilt testing at 80 degrees
Number of subjects: 150
Study 7788917 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilt testing at 70 degrees with 1.5 micrograms/min isoproterenol infusion
Number of subjects: 150
Study 7788917 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilt testing at 70 degrees with 3 micrograms/min isoproterenol infusion
Number of subjects: 150
Study 7788917 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilt testing at 70 degrees with 5 micrograms/min isoproterenol infusion
Number of subjects: 150
Study 7788917 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilt testing during 3 micrograms/min isoproterenol infusion
Number of subjects: 150
Study 7788917 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilt testing during 5 micrograms/min isoproterenol infusion
Number of subjects: 150
Study 2531611 — intervention group
Group type: EXPERIMENTAL
Intervention: MPA alone
Number of subjects: 84
Study 2531611 — intervention group
Group type: EXPERIMENTAL
Intervention: MPA plus psychotherapy
Number of subjects: 84
Study 2531611 — intervention group
Group type: COMPARATOR
Intervention: Placebo alone
Number of subjects: 84
Study 2531611 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus psychotherapy
Number of subjects: 84
Study 1098155 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg mebendazole twice a day for three days
Number of subjects: 70
Study 1098155 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg mebendazole twice a day for four days
Number of subjects: 70
Study 1098155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 31909861 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable scaffold (BRS) derived PSP score
Number of subjects: 2348
Study 31909861 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal sizing
Number of subjects: 2348
Study 31909861 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal predilation
Number of subjects: 2348
Study 31909861 — intervention group
Group type: EXPERIMENTAL
Intervention: New PSP scoring system
Number of subjects: 2348
Study 30646948 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led, telephone-based follow-up
Number of subjects: 771